Association of HER2 amplification or overexpression with overall survival in advanced upper gastrointestinal adenocarcinomas
{{output}}
Background: Advanced esophageal (EAC), gastroesophageal junction (GEJAC) and gastric (GAC) adenocarcinomas with HER2 amplification or overexpression (HER2+) are routinely treated with trastuzumab. However, it remains unclear if H... ...
